Time-restricted Feeding in MASLD
Recruiting
N/A
Interventional Study
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Universität des Saarlandes · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) currently focuses on lifestyle changes, including dietary adjustments and increased physical activity. Intermittent fasting is a specific dietary approach in which food intake is restricted for certain periods. Recent scientific evidence suggests that intermittent fasting can positively influence body we…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18 and 75 years
* Body mass index (BMI) \> 25 kg/m²
* MASLD grade 3 with CAP ≥ 280 dB/m, excluding liver damage
* Liver stiffness \< 13 kPa
* Ability to understand the study and the individual consequences of participating in the study
* Signed and dated consent form before th…
Contacts